Injured by Celebrex Side Effects?
Celebrex is the only COX-2 inhibitor still on the market in the United States. The popular painkiller has been used by millions of Americans and Pfizer is expecting over $2 Billion in sales from the drug Celebrex in 2007 alone.
Celebrex is however linked to serious adverse side effects including heart attacks, strokes and Stevens Johnson Syndrome (SJS).
Update: Schmidt & Clark is no longer accepting Celebrex cases.
What is the Problem?
The Food & Drug Administration in 2005 asked their advisory committee to examine the drug Celebrex to determine whether it offered enough benefits to the consumer stay on the market and whether or not they needed to add stronger warnings to the package inserts. The advisory committee indicated that Celebrex elevates the chances of cardiovascular problems.
Dr. Garret Fitzgerald, a researcher at the University of Pennsylvania, has told the US regulatory panel governing the drug Celebrex that all COX-2 inhibitors increase the risk of heart attacks and strokes. Dr. Fitzgerald has indicated that the body will react the same to Celebrex as it does to Vioxx or Bextra, which have both been removed from the market. Furthermore, Dr. Fitzgerald said that Celebrex creates an imbalance in the body's cardiovascular system that may lead to an increased risk of heart attacks and strokes.
Celebrex Side Effects & Lawsuit News (National)
| International sales lift Pfizer 2Q profit - Forbes Pfizer Inc. on Wednesday said its second-quarter profit more than doubled as restructuring charges declined and the weak dollar helped lift overseas revenue, offsetting new generic competition and enabling the company to just beat Wall Street ... Weak dollar, foreign sales boost drugmakers - Forbes Profits posted Wednesday by Pfizer Inc. and Wyeth show a common theme among pharmaceutical companies - nearly all the growth they're seeing these days is overseas, driven by emerging markets and the weak dollar. U.K.-based GlaxoSmithKline PLC, which ... S&P Picks and Pans: Fannie Mae, Freddie Mac, Yahoo, WaMu, Pfizer ... - BusinessWeek From Standard & Poor's Equity Research June-quarter adjusted EPS of $0.55, vs. $0.42, is a penny below our estimate. Revenue rose 9%, 7% from forex. Key drivers were Lipitor (ex-U.S.), Lyrica and Celebrex. But U.S. Chantix sales fell 35% on new black ... Pfizer Profit More Than Doubles on Sales Outside U.S. (Update3) - Bloomberg July 23 (Bloomberg) -- Pfizer Inc. , the world's largest drugmaker, said second-quarter profit more than doubled as the company cut costs and boosted sales outside the U.S., where it benefited from favorable exchange rates. Net income increased to $2 ... Pfizer Beats EPS Target by a Penny - Street.Com Pfizer PFE posted greater-than-expected profit and revenue for the second quarter Wednesday. Foreign exchange rates helped to balance a highly competitive statin market, loss of some product exclusivity and safety concerns that marred U.S. sales of ... Pfizer profit doubles, but anti-smoking drug lags - San Diego Union-Tribune NEW YORK ? Pfizer Inc Wednesday said quarterly earnings more than doubled on higher sales of its prescription drugs and lower expenses, but its Chantix quit-smoking drug lost more than a third of its U.S. sales amid safety concerns. The company ... Pfizer's 2Q Net More Than Doubles, Wyeth's Drops 6.4% - CNN Money Pfizer Inc.'s (PFE) second-quarter net income more than doubled amid cost- cutting and lower restructuring charges, while Wyeth (WYE) had a 6.4% decrease, weighed down by restructuring costs. Pfizer reaffirmed its 2008 outlook, while Wyeth boosted ... Pfizer, Inc. Q2 2008 Earnings Call Transcript - Seekingalpha.com Good morning and thank you for joining us today to review our second quarter 2008 performance. I am here where Jeff Kindler, Chairman and CEO; Frank D'Amelio, Chief Financial Officer, and other members of our senior management team. The financial ... Pfizer Reports Second-Quarter 2008 Results - MSN MoneyCentral Pfizer Inc PFE today reported financial results for the second-quarter 2008. The Company recorded revenues of $12.1 billion, an increase of 9% compared with $11.1 billion in the year-ago quarter. In the U.S., revenues were $4.8 billion, a decrease of ... Several recent non-approvable decisions in the osteoarthritis market ... - PR Inside After three years of decline, market sales grew by 0.8% (2006-07) to reach $4 billion in the 7MM in 2007. Driving growth was an increase in sales of COX-2, non-narcotic analgesic and corticosteroid classes. Market sales will reach $5.5 billion by ... |
